The future of GLP-1 research As GLP-1s continue to reshape the treatment of type 2 diabetes and obesity (along with an expanding list of potential indications), real-world evidence will be essential for optimizing their use, ensuring access, and tailoring treatments to the individual needs of patients
One of the potential risks of Ozempic is the development of gallstones and related problems, such as pancreatitis
Roughly 25 to 35 percent of the weight that GLP-1 patients lose is lean mass, according to a meta-analysis published in March
More serious but rare adverse effects include: Pancreatitis : Seek immediate medical attention if you experience severe, persistent abdominal pain radiating to the back, particularly if accompanied by vomiting Diabetic retinopathy complications : The SmPC notes that rapid improvement in glucose control has been associated with temporary worsening of diabetic retinopathy, particularly in patients with pre-existing retinopathy and those on insulin [1] [18] Acute kidney injury : Particularly in the context of severe dehydration from gastrointestinal side effects Gallbladder disease : Rapid weight loss may increase the risk of gallstones Thyroid considerations : Semaglutide has been associated with thyroid C-cell tumours in rodent studies, though the relevance to humans remains uncertain
There havent been any direct studies comparing Ozempic-related blood sugar control with or without antidepressants